Ampyra for Optic Neuritis in MS
Bio2RDF uri
Ampyra for Optic Neuritis in MS
Bio2RDF identifier
NCT01337986
Bio2RDF namespace
clinicaltrials
Bio2RDF uri
http://bio2rdf.org/clinicaltrials:NCT01337986
identifiers.org URI
actual enrollment [clinicaltrials_vocabulary:actual-enrollment]
arm group [clinicaltrials_vocabulary:arm-group]
authority [clinicaltrials_vocabulary:authority]
brief summary [clinicaltrials_vocabulary:brief-summary]
Fifty subjects will be ...... n for the latter three weeks.
brief title [clinicaltrials_vocabulary:brief-title]
Ampyra for Optic Neuritis in MS
clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
collaborator [clinicaltrials_vocabulary:collaborator]
completion date [clinicaltrials_vocabulary:completion-date]
2013-12-01T00:00:00Z
condition [clinicaltrials_vocabulary:condition]
condition browse [clinicaltrials_vocabulary:condition-browse]
condition mesh [clinicaltrials_vocabulary:condition-mesh]
country [clinicaltrials_vocabulary:country]
detailed description [clinicaltrials_vocabulary:detailed-description]
Optic neuritis (ON) is ...... n for the latter three weeks.
download date [clinicaltrials_vocabulary:download-date]
ClinicalTrials.gov processed this data on August 10, 2015
eligibility [clinicaltrials_vocabulary:eligibility]
firstreceived date [clinicaltrials_vocabulary:firstreceived-date]
2011-04-13T00:00:00Z
has expanded access [clinicaltrials_vocabulary:has-expanded-access]
intervention [clinicaltrials_vocabulary:intervention]
intervention browse [clinicaltrials_vocabulary:intervention-browse]
is fda regulated [clinicaltrials_vocabulary:is-fda-regulated]
is section 801 [clinicaltrials_vocabulary:is-section-801]
keyword [clinicaltrials_vocabulary:keyword]
Contrast Sensitivity
Dalfampridine
Fampridine
Multiple Sclerosis
Optic Neuritis
Remote Optic Neuritis
lastchanged date [clinicaltrials_vocabulary:lastchanged-date]
2014-02-14T00:00:00Z
lead sponsor [clinicaltrials_vocabulary:lead-sponsor]
link [clinicaltrials_vocabulary:link]
location [clinicaltrials_vocabulary:location]
nct id [clinicaltrials_vocabulary:nct-id]
NCT01337986
number of arms [clinicaltrials_vocabulary:number-of-arms]
official title [clinicaltrials_vocabulary:official-title]
Dalfampridine After Optic Neuritis to Improve Visual Function in Multiple Sclerosis
org study id [clinicaltrials_vocabulary:org-study-id]
Ampyra Vision 2011 RTN
overall official [clinicaltrials_vocabulary:overall-official]
overall status [clinicaltrials_vocabulary:overall-status]
oversight [clinicaltrials_vocabulary:oversight]
phase [clinicaltrials_vocabulary:phase]
primary completion date [clinicaltrials_vocabulary:primary-completion-date]
2013-12-01T00:00:00Z
reference [clinicaltrials_vocabulary:reference]
responsible party [clinicaltrials_vocabulary:responsible-party]
secondary id [clinicaltrials_vocabulary:secondary-id]
WU HRPO# : 201104126
source [clinicaltrials_vocabulary:source]
start date [clinicaltrials_vocabulary:start-date]
2011-05-01T00:00:00Z
study design [clinicaltrials_vocabulary:study-design]
study type [clinicaltrials_vocabulary:study-type]
url [clinicaltrials_vocabulary:url]
verification date [clinicaltrials_vocabulary:verification-date]
2014-02-01T00:00:00Z
identifier
clinicaltrials:NCT01337986